Search results
Showing 61 to 75 of 264 results for carcinoma
Pemetrexed for the first-line treatment of non-small-cell lung cancer (TA181)
Evidence-based recommendations on pemetrexed for untreated non-small-cell lung cancer in adults.
Evidence-based recommendations on nivolumab (Opdivo) for treating locally advanced unresectable or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy.
Evidence-based recommendations on bulevirtide (Hepcludex) for chronic hepatitis D in adults.
Evidence-based recommendations on photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic skin lesions). This involves applying (or sometimes injecting) a photosensitising agent and using light to activate it, destroying the tumour cells.
View recommendations for HTG99Show all sections
VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions (HTG388)
Evidence-based recommendations on the VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions.
Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer in adults.
This guideline covers new buildings and communal outdoor areas. The aim is to ensure there are enough shady areas to protect people from overexposure to the sun.
Evidence-based recommendations on nivolumab (Opdivo) as a possible treatment for completely resected oesophageal or gastro-oesophageal junction cancer in adults.
Endoscopic submucosal dissection of oesophageal dysplasia and neoplasia (HTG228)
Evidence-based recommendations on endoscopic submucosal dissection (ESD) of oesophageal dysplasia and neoplasia. This involves inserting a long camera through the mouth into the oesophagus to view the area and removing the abnormal part with special instruments.
View recommendations for HTG228Show all sections
Sections for HTG228
Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer (HTG522)
Evidence-based recommendations on transurethral laser ablation for recurrent non-muscle-invasive bladder cancer in adults. This involves using a laser inserted into the bladder to destroy the cancer cells.
View recommendations for HTG522Show all sections
Endoscopic radiofrequency ablation for squamous dysplasia of the oesophagus (HTG346)
Evidence-based recommendations on endoscopic radiofrequency ablation for squamous dysplasia of the oesophagus. This involves using radiofrequency (heat) energy to destroy the abnormal cells and to promote the growth of healthy squamous cells.
Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer (HTG487)
Evidence-based recommendations on intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer in adults. This involves using microwaves to improve the effect of the chemotherapy given directly into the bladder.
View recommendations for HTG487Show all sections
Laparoscopic nephrectomy (including nephroureterectomy) (HTG84)
Evidence-based recommendations on laparoscopic nephrectomy (including nephroureterectomy). This involves making small incisions (keyhole surgery) to remove the damaged kidney, or kidney, ureter and surrounding tissue.
View recommendations for HTG84Show all sections
Sections for HTG84
This guideline covers identifying children, young people and adults with symptoms that could be caused by cancer. It outlines appropriate investigations in primary care, and selection of people to refer for a specialist opinion. It aims to help people understand what to expect if they have symptoms that may suggest cancer.
Show all sections
Sections for NG12
Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer (TA707)
Evidence-based recommendations on Nivolumab (Opdivo) for previously treated unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma in adults.